AZD 9550
Alternative Names: AZD-9550Latest Information Update: 22 Dec 2023
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Hepatoprotectants; Peptides; Small molecules
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-alcoholic steatohepatitis
Most Recent Events
- 13 Nov 2023 AstraZeneca completes a phase I trial in Non-alcoholic steatohepatitis (In volunteers) in UK (SC) (NCT05848440) (EudraCT2022-003308-34)
- 29 Sep 2023 Phase-I/II clinical trials in Non-alcoholic steatohepatitis in Germany (SC) (NCT06151964)
- 02 May 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in United Kingdom (IV) (NCT05848440)